Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press4410.17650/1726-9776-2011-7-1-10-15LECTUREЛЕКЦИЯTREATMENT FOR STAGE I NONSEMINOMATOUS TESTICULAR GERM CELL TUMORSЛЕЧЕНИЕ НЕСЕМИНОМНЫХ ГЕРМИНОГЕННЫХ ОПУХОЛЕЙ ЯИЧКА I СТАДИИBurovaE. A.БуроваЕ. А.
Russian Federation
doc.elenaburova@gmail.ruBulanovA. A.БулановА. А.
Russian Federation
doc.elenaburova@gmail.ruTryakinA. A.ТрякинА. А.
Russian Federation
doc.elenaburova@gmail.ruFedyaninM. Yu.ФедянинМ. Ю.
Russian Federation
doc.elenaburova@gmail.ruMatveevV. B.МатвеевВ. Б.
Russian Federation
doc.elenaburova@gmail.ruTulandinS. A.ТюляндинC. А.
Russian Federation
doc.elenaburova@gmail.ruRussian Cancer Research Center, Russian Academy of Medical Sciences, MoscowРОНЦ им. Н.Н. Блохина РАМН, Москва300320117110152407201424072014https://oncourology.abvpress.ru/oncur/article/view/44

Overall survival is about 100 % in patients with stage I testicular germ cell tumors after orchofuniculectomy, which is achieved, by applying alternative adjuvant approaches. Methods, such as a follow-up, chemotherapy or retroperitoneal lymphadenectomy, may be used to treat nonseminomatous germ cell tumors. The paper shows the main advantages and disadvantages of the above treatment options.

Общая выживаемость больных с герминогенными опухолями яичка I стадии после выполнения им орхифуникулэктомии составляет почти 100 %, что достигается за счет использования альтернативных адъювантных подходов. При лечении несеминомных герминогенных опухолей могут применяться следующие методы: динамическое наблюдение, химиотерапия или забрюшинная лимфаденэктомия. В статье представлены основные преимущества и недостатки названных лечебных опций.

nonseminomatous testicular germ cell tumorstreatmentfollow-upchemotherapyretroperitoneal lymphadenectomyнесеминомные герминогенные опухоли яичкалечениединамическое наблюдениехимиотерапиязабрюшинная лимфаденэктомия1. Spermon J.R., Roeleveld T.A., Van der Poel H.G. et al. Comparison of surveillance and retroperitoneal lymph node dissection in stage I nonseminomatous germ cell tumors. Urology 2002;59:923–9.Spermon J.R., Roeleveld T.A., Van der Poel H.G. et al. Comparison of surveillance and retroperitoneal lymph node dissection in stage I nonseminomatous germ cell tumors. Urology 2002;59:923–9.2. Read G., Stenning S.P., Cullen M.H. et al. Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J Clin Oncol 1992;10:1762–8.Read G., Stenning S.P., Cullen M.H. et al. Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J Clin Oncol 1992;10:1762–8.3. Sogani P.C., Perrotti M., Herr H.W. et al. Clinical stage I testis cancer: long-term outcome of patients on surveillance. J Urol 1998;159:855–8.Sogani P.C., Perrotti M., Herr H.W. et al. Clinical stage I testis cancer: long-term outcome of patients on surveillance. J Urol 1998;159:855–8.4. Cullen M.H., Stenning S.P., Parkinson M.C. et al. Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. J Clin Oncol 1996;14:1106–13.Cullen M.H., Stenning S.P., Parkinson M.C. et al. Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. J Clin Oncol 1996;14:1106–13.5. Maroto P., Garcia del Muro X., Aparicio J. et al. Multicentre risk-adapted management for stage I non-seminomatous germ cell tumours. Ann Oncol 2005;16(12):1915–20.Maroto P., Garcia del Muro X., Aparicio J. et al. Multicentre risk-adapted management for stage I non-seminomatous germ cell tumours. Ann Oncol 2005;16(12):1915–20.6. Vergouwe Y., Steyerberg E.W., Eijkemans M.J. et al. Predictors of occult metastasis in clinical stage I nonseminoma: a systematic review. J Clin Oncol 2003;21(22):4092–9.Vergouwe Y., Steyerberg E.W., Eijkemans M.J. et al. Predictors of occult metastasis in clinical stage I nonseminoma: a systematic review. J Clin Oncol 2003;21(22):4092–9.7. Albers P., Siener R., Kliesch S. et al. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. J Clin Oncol 2003;21(8):1505–12.Albers P., Siener R., Kliesch S. et al. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. J Clin Oncol 2003;21(8):1505–12.8. Foster R.S., Roth B.J. Clinical stage I nonseminoma: surgery versus surveillance. Semin Oncol 1998;25:145–53.Foster R.S., Roth B.J. Clinical stage I nonseminoma: surgery versus surveillance. Semin Oncol 1998;25:145–53.9. Stephenson A.J., Bosl G.J., Bajorin D.F. et al. Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion. J Urol 2005;174(2):557–60.Stephenson A.J., Bosl G.J., Bajorin D.F. et al. Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion. J Urol 2005;174(2):557–60.10. Kondagunta G.V., Sheinfeld J., Mazumdar M. et al. Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy. J Clin Oncol 2004;22:464–7.Kondagunta G.V., Sheinfeld J., Mazumdar M. et al. Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy. J Clin Oncol 2004;22:464–7.11. Fizazi K., Auperin A., Le Moulec S. et al. Stage I seminoma: Can 18flurorodeoxyglucose positron emission tomography (FDG-PET) predict occult dissemination? A phase II study. 2008 Genitourinary Cancers Symposium; abstr 280.Fizazi K., Auperin A., Le Moulec S. et al. Stage I seminoma: Can 18flurorodeoxyglucose positron emission tomography (FDG-PET) predict occult dissemination? A phase II study. 2008 Genitourinary Cancers Symposium; abstr 280.12. Dieckmann K., Albers P., Siener R. et al. One course of adjuvant PEB versus retroperitoneal lymph node dissection in patients with stage I non-seminomatous germcell tumors (NSGCT). Results of the German prospective multicenter trial (Association of Urological Oncology (AUO)/German Testicular Cancer Study Group[GTCSG] trial01-94. Proc Am Ass Clin Oncol 2006;24:220;abstr 4512.Dieckmann K., Albers P., Siener R. et al. One course of adjuvant PEB versus retroperitoneal lymph node dissection in patients with stage I non-seminomatous germcell tumors (NSGCT). Results of the German prospective multicenter trial (Association of Urological Oncology (AUO)/German Testicular Cancer Study Group[GTCSG] trial01-94. Proc Am Ass Clin Oncol 2006;24:220;abstr 4512.13. Gimmi S., Sonntag R., Brunner K. et al. Adjuvant treatment of high risk (HR) clinical stage I testicular carcinoma (TC) with cisplatin (C), bleomycin (B) and vinblastine (V) or etoposide (E). Proc Am Soc Clin Oncol 1990;9:140.Gimmi S., Sonntag R., Brunner K. et al. Adjuvant treatment of high risk (HR) clinical stage I testicular carcinoma (TC) with cisplatin (C), bleomycin (B) and vinblastine (V) or etoposide (E). Proc Am Soc Clin Oncol 1990;9:140.14. Pont J., Albrecht W., Postner G. et al. Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. J Clin Oncol 1996;14:441–8.Pont J., Albrecht W., Postner G. et al. Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. J Clin Oncol 1996;14:441–8.15. Bohlen D., Borner M., Sonntag R.W. et al. Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors. J Urol 1999;161:1148–52.Bohlen D., Borner M., Sonntag R.W. et al. Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors. J Urol 1999;161:1148–52.16. Dearnaley D.P., Fossa S.D., Kaye S.B. et al. Adjuvant bleomycin, vincristine and cisplatin (BOP) for high-risk stage I non-eminomatous germ cell tumours: a prospective trial (MRC TE17). Br J Cancer 2005;92(12):2107–13.Dearnaley D.P., Fossa S.D., Kaye S.B. et al. Adjuvant bleomycin, vincristine and cisplatin (BOP) for high-risk stage I non-eminomatous germ cell tumours: a prospective trial (MRC TE17). Br J Cancer 2005;92(12):2107–13.17. Amato R.J., Ro J.Y., Ayala A.G., Swanson D.A. Risk-adapted treatment for patients with clinical stage I nonseminomatous germ cell tumor of the testis. Urology 2004;63(1):144–8.Amato R.J., Ro J.Y., Ayala A.G., Swanson D.A. Risk-adapted treatment for patients with clinical stage I nonseminomatous germ cell tumor of the testis. Urology 2004;63(1):144–8.18. Pectasides D., Skarlos D., Dimopoulos A.M. et al. Two cycles of carboplatin-based adjuvant chemotherapy for high-risk clinical stage I and stage IM non-seminomatous germ cell tumours of the testis: a HECOG trial. Anticancer Res 2003;23:4239–44.Pectasides D., Skarlos D., Dimopoulos A.M. et al. Two cycles of carboplatin-based adjuvant chemotherapy for high-risk clinical stage I and stage IM non-seminomatous germ cell tumours of the testis: a HECOG trial. Anticancer Res 2003;23:4239–44.19. Horwich A., Sleijfer D.T., Fossa S.D. et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 1997;15:1844–52.Horwich A., Sleijfer D.T., Fossa S.D. et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 1997;15:1844–52.20. De Santis M., Albrecht W., Pont J. Impact of cytotoxic treatment on long-term fertility in patients with germ-cell cancer. Int J Cancer 1999;83:864–5.De Santis M., Albrecht W., Pont J. Impact of cytotoxic treatment on long-term fertility in patients with germ-cell cancer. Int J Cancer 1999;83:864–5.21. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: The SWENOTECA Management Program. J Clin Oncol 2009;27:2122–8.Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: The SWENOTECA Management Program. J Clin Oncol 2009;27:2122–8.22. Rustin G.J., Mead G.M., Stenning S.P. et al. Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197 – the National Cancer Research Institute Testis Cancer Clinical Studies Group. J Clin Oncol 2007;25(11):1310–5.Rustin G.J., Mead G.M., Stenning S.P. et al. Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197 – the National Cancer Research Institute Testis Cancer Clinical Studies Group. J Clin Oncol 2007;25(11):1310–5.